BMS-Celgene deal: CEO looking to the ‘evolution’ of market with cell therapies
BMS' CEO explains that the deal will help the company to ‘participate in the growth and evolution’ of oncology, spearheaded by cellular therapies.
Archives for January 9, 2019
From CAR-T to CAAR-T: Funding drives biotech into emerging space
Cabaletta Bio closed a $50m Series B funding enabling the company to develop further in the CAAR-T space.
Janssen offers $818m to access CRISPR tech
Janssen has licensed Locus’ CRISPR-Cas3 technology to target two bacterial pathogens for the development of treatments for infections.